Latham advised Zentalis Pharmaceuticals on the deal. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the pricing of its initial public offering of 9,180,000 shares of common stock…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now